8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 2, 2018

PFIZER INC.
(Exact name of registrant as specified in its charter)

Delaware	1-3619	13-5315170
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
235 East 42nd Street New York, New York(Address of principal executive offices)		10017  (Zip Code)

Registrant's telephone number, including area code:

(212) 733-2323 Not Applicable
(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[   ] Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[   ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[   ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[   ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company  [   ]     If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.   [   ]

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On March 5, 2018, the Board of Directors of Pfizer Inc. (the “Company”) elected Dr. Dan R. Littman to serve as a member of the Company’s Board of Directors, effective immediately. In addition, he was appointed to the Corporate Governance Committee and the Science and Technology Committee of the Board.

Dr. Littman has been provided an indemnification agreement and will receive compensation in accordance with the Company’s standard arrangements for non-employee directors.

The press release, dated March 5, 2018, announcing the election of Dr. Littman is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Separately, on March 2, 2018, Mr. Stephen W. Sanger, who has served as a director of the Company since 2009, notified the Company of his intention to retire from the Board of Directors at the Annual Meeting of Shareholders in April 2018.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits
Exhibit No.	Description
99.1	Press Release of Pfizer Inc. dated March 5, 2018

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release of Pfizer Inc. dated March 5, 2018

SIGNATURE

Under the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the authorized undersigned.

	PFIZER INC.
Dated: March 6, 2018	By:   /s/ Margaret M. Madden_____          Margaret M. Madden
	Title:  Senior Vice President and Corporate Secretary              Chief Governance Counsel

EX-99.1

Exhibit 99.1

For immediate release	Media Contact:
March 5, 2018	Joan Campion
	(212) 733-2798
	Investor Contact:
	Ryan Crowe
	(212) 733-8160

DAN R. LITTMAN ELECTED TO PFIZER’S BOARD OF DIRECTORS

NEW YORK, N.Y., March 5 – Pfizer Inc. today announced the election of Dr. Dan R. Littman to its Board of Directors. Dr. Littman, age 65, was also appointed to the Corporate Governance and Science and Technology Committees of Pfizer’s Board.

Dr. Littman is the Helen L. and Martin S. Kimmel Professor of Molecular Immunology at the Skirball Institute of Biomolecular Medicine of NYU Langone Medical Center and an Investigator of the Howard Hughes Medical Institute. Prior to joining NYU in 1995, he was a Professor of Microbiology and Immunology at the University of California, San Francisco.

Dr. Littman is also a member of the National Academy of the Sciences and the Institute of Medicine, and is a Fellow of the American Academy of Arts and Sciences and the American Academy of Microbiology.

Dr. Littman received an A.B. in Biochemical Sciences from Princeton University and an M.D. and Ph.D. from Washington University School of Medicine.

“We are pleased to welcome a renowned immunologist to Pfizer’s Board of Directors,” said Ian Read, Chairman and Chief Executive Officer, Pfizer. “Dr. Littman has made extraordinary scientific contributions throughout his career and will be a tremendous asset to the company. The addition of Dan to the board helps to ensure that Pfizer will continue to benefit from a breadth and diversity of experience.”

About Pfizer Inc.

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best - known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com. In addition, to learn more, please visit us on www.pfizer.com and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.